UK markets closed
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • FTSE 250

    20,338.96
    +93.53 (+0.46%)
     
  • AIM

    933.20
    +4.84 (+0.52%)
     
  • GBP/EUR

    1.1820
    +0.0002 (+0.02%)
     
  • GBP/USD

    1.2139
    -0.0064 (-0.52%)
     
  • BTC-GBP

    20,434.87
    +620.07 (+3.13%)
     
  • CMC Crypto 200

    574.64
    +3.36 (+0.59%)
     
  • S&P 500

    4,280.15
    +72.88 (+1.73%)
     
  • DOW

    33,761.05
    +424.38 (+1.27%)
     
  • CRUDE OIL

    91.88
    -2.46 (-2.61%)
     
  • GOLD FUTURES

    1,818.90
    +11.70 (+0.65%)
     
  • NIKKEI 225

    28,546.98
    +727.65 (+2.62%)
     
  • HANG SENG

    20,175.62
    +93.19 (+0.46%)
     
  • DAX

    13,795.85
    +101.34 (+0.74%)
     
  • CAC 40

    6,553.86
    +9.19 (+0.14%)
     

VIRBAC: growth in revenue in the first half of 2022 of +12.0% at comparable exchange rates (+16.4% at real rates), driven by good performance in all areas

  • Oops!
    Something went wrong.
    Please try again later.
·5-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Virbac
Virbac

KEY FIGURES

Revenue in first half of 2022 -Provisional

 

€616.4 million

Growth at constant exchange rates
and scope 1


 

+12.0% including

companion animals +14.2%
 
food-producing animals +9.9%

Growth at constant
exchange rates

 

+12.0%

 

Overall
change


 

+16.4%

 

 
1 Growth at constant exchange rates and scope corresponds to organic growth of sales, excluding exchange rate variations, by calculating the indicator for the financial year in question and the indicator for the previous financial year on the basis of identical exchange rates (the exchange rate used is the previous financial year), and excluding change in scope, by calculating the indicator for the financial year in question on the basis of the scope of consolidation for the previous financial year.


Quarterly consolidated revenue
Our second-quarter revenue reached €298.3 million, or a +13.5% increase compared to the same period in 2021. At constant exchange rates, growth was +7.8%, driven by good performance in both the companion animals and food producing animals segments, in a context of market slowdown. It should be noted that our actual performance for the quarter was favorably impacted by the appreciation of certain currencies, such as the US dollar, the Indian rupee, the Brazilian real, and the Mexican peso. At area level, our growth is mainly driven by the performance of the United States, particularly in the dental and dermatology ranges and recently launched products range (Clomicalm, Itrafungol, the petfood and the food producing animals range), by that of the Asia-Pacific zone, where India and Australia continue to benefit from a favorable momentum, and finally Latin America, driven by double-digit growth in Brazil and Mexico.


Cumulative consolidated revenue at the end of June
For the first half of the year overall, our revenues were €616.4 million, compared with €529.4 million, representing an overall increase of +16.4% compared with the same period in 2021. Adjusted for the favorable impact of exchange rates, revenue shows growth of +12.0%. This growth benefited in part from a favorable baseline effect representing 1 point of growth in revenue, attributable to new products acquired starting in the second quarter of 2021.

All areas are growing organically at the end of June. It should be noted, however, that double-digit growth in Europe has stalled in the last quarter, due to the slowdown in the market as anticipated in our annual outlook. Thus, the sales in this area increased by +6.8% at real rates (+6.2% at constant rates), thanks mainly to the contribution of the United Kingdom, France and Italy. The area is supported by the strong dynamism of companion animals ranges (in particular petfood, specialties, and vaccines), which compensate for the withdrawal of ranges intended for food producing animals. In Asia-Pacific, the development at real rates is +19.8% (+15% at constant exchange rates). Australia and India are driving growth in the region, generating more than 85% of the latter, in particular on products destined for cattle, which makes it possible to largely compensate for the withdrawal of China, which was heavily impacted by lockdowns at the beginning of the year and which, despite a rebound since May, remains down at the end of June. In Latin America, activity grew by +25.1% at real rates (+14.6% at constant exchange rates), thanks in particular to contributions from Brazil and Mexico. Finally, in the United States, activity increased by +32.2% (+19.9% at constant exchange rates). It benefits from sustained sales on new products launched in 2021 (Clomicalm and Itrafungol) and those launched in early 2022 (petfood, and Tulissin for the food producing animals segment), as well as good performance on the dental and dermatology ranges.


In terms of species, revenue in the companion animal segment grew overall by +17.9% at real rates (+14.2% at constant exchange rates), mainly driven by very good double-digit growth in the petfood, specialty, dermatology and hygiene ranges, as well as vaccines for dogs and cats. The food producing animals segment also showed strong growth of +15.0% at real rates (+9.9% at constant exchange rates), mainly driven by the ruminant sector (+14.2% at constant exchange rates); and the aquaculture segment (+5.1% at constant rates) compared to the same period in 2021.

Covid-19 health crisis and the war in Ukraine
We continue to face significant production, logistical and supply constraints with regard to certain intermediaries, and more recently, significant inflationary impacts on our costs (energy, raw materials, transportation, etc.).


Outlook
The activity in the first half of the year reinforces our perspective. Revenue growth at constant rates and scope should be in the range of 5% to 10%. The ratio of “current operating profit before depreciation of assets arising from acquisitions” to “revenue” should be around 15% at constant exchange rates, despite the inflationary impacts (with a deliberate overinvestment in R&D of approximately 1 percentage point of revenue compared to 2021). Finally, our debt relief should be around €60 million, excluding dividends, at constant scope and exchange rates.


CONSOLIDATED FIGURES
Non-audited figures 
in millions of euros

2022

2021

Growth

Growth 
at constant exchange rates 1

Growth 
at constant exchange rates and scope 1

First quarter revenue

318.1

266.5

+19.3%

+16.2%

+16.2%

Second quarter revenue

298.3

262.9

+13.5%

+7.8%

+7.8%

Revenue for first half year

616.4

529.4

+16.4%

+12.0%

+12.0%





A lifelong commitment to animal health

At Virbac, we provide innovative solutions to veterinarians, farmers and animal owners in more than 100 countries around the world. Covering more than 50 species, our range of products and services enables us to diagnose, prevent and treat the majority of pathologies. Every day, we are committed to improving the quality of life of animals and to shaping the future of animal health together.

Virbac: NYSE Euronext - compartment A – ISIN code: FR0000031577 / MNEMO: VIRP
Financial Affairs Department: tel. 04 92 08 71 32 - email: finances@virbac.com - Website: corporate.virbac.com

Attachment


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting